Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer

Trial Profile

Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Bevacizumab; Capecitabine
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 04 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 16 Feb 2018 Planned initiation date changed from 30 Jan 2018 to 30 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top